Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00137111 · ClinicalTrials.gov registry record · Phase 3
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
A Phase 3 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 501
- Enrollment target
NCT00137111: Completed Phase 3 study, sponsored by St. Jude Children's Research Hospital.
NCT00137111 is a Phase 3 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 501 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00137111, a Phase 3 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 501 participants
- Enrollment target
Study Summary
The primary objective is to estimate the overall event-free survival of children at least one year of age at diagnosis who are treated with risk-directed therapy and to monitor the molecular remission induction rate.
Primary Outcome
EFS was measured from the start of on-study to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Failure to enter remission was considered an event at time zero. Measurement was determined by Kaplan-Meyer estimate.
Interventions
- DRUG Prednisone, Dexamethasone, Vincristine, Daunorubicin
- DRUG Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase
- DRUG Methotrexate, Cyclophosphamide, Cytarabine, Etoposide
- DRUG Mercaptopurine, Imatinib
- PROCEDURE chemotherapy, intrathecal chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 501 participants |
| Start Date | 2000-07-08 |
| Est. Completion | 2014-04 |
| Phase | Phase 3 |
What the finished NCT00137111 record still lists
NCT00137111 is an interventional study that assigns participants to a tested intervention. The registered 501 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 5 interventions - of which Prednisone, Dexamethasone, Vincristine, Daunorubicin is the first listed.
NCT00137111 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00137111 about?
NCT00137111 is a clinical study titled "Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia". The primary objective is to estimate the overall event-free survival of children at least one year of age at diagnosis who are treated with risk-directed therapy and to monitor the molecular remission induction rate.
What is the current status of trial NCT00137111?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 501 participants. The study started on 2000-07-08. Estimated completion is 2014-04.
What interventions are being tested in trial NCT00137111?
The interventions under investigation include: Prednisone, Dexamethasone, Vincristine, Daunorubicin (DRUG), Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase (DRUG), Methotrexate, Cyclophosphamide, Cytarabine, Etoposide (DRUG), Mercaptopurine, Imatinib (DRUG), chemotherapy, intrathecal chemotherapy (PROCEDURE).
Who is sponsoring clinical trial NCT00137111?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00137111's enrollment target sits among peer trials
501 743rd of 2000 higher than 1,257 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04442022 · 501 participants · Phase 2
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06934525 · 501 participants · NA
Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings
- NCT05646381 · 502 participants · Phase 2
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
- NCT05897632 · 502 participants · NA
CARE-CP (Testing a Cardiovascular Ambulatory Rapid Evaluation for Patients With Chest Pain)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI